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I. Introduction
The American College of Cardiology/American Heart Association
(ACC/AHA) Task Force on Practice Guidelines was formed to
make recommendations regarding the appropriate use of diagnostic
tests and therapies for patients with known or suspected cardiovas-
cular disease. Coronary artery bypass graft (CABG) surgery is
among the most common operations performed in the world and
accounts for more resources expended in cardiovascular medicine
than any other single procedure. Since the original Guidelines were
published in 1991, there has been considerable evolution in the
surgical approach to coronary disease, and at the same time there
have been advances in preventive, medical, and percutaneous
catheter approaches to therapy. These revised guidelines are based
on a computerized search of the English literature since 1989, a
manual search of final articles, and expert opinion.
As with other ACC/AHA guidelines, this document uses ACC/
AHA classifications I, II, and III as summarized below:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or treatment is useful
and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness or efficacy
of a procedure.
Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well established
by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is not
useful/effective and in some cases may be harmful.
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TABLE 1. Northern New England Cardiovascular Disease Study Group: Preoperative Estimation of Risk of Mortality, Cerebrovascular
Accident (CVA), and Mediastinitis (for Use Only in Isolated CABG Surgery)
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II. Outcomes
A. Hospital Outcomes
Seven core variables (priority of operation, age, prior heart
surgery, sex, left ventricular [LV] ejection fraction [EF],
percent stenosis of the left main coronary artery, and number
of major coronary arteries with significant stenoses) are the
most consistent predictors of mortality after coronary artery
surgery. The greatest risk is correlated with the urgency of
operation, advanced age, and 1 or more prior coronary bypass
surgeries. Additional variables that are related to mortality
include coronary angioplasty during index admission; recent
myocardial infarction (MI); history of angina, ventricular
arrhythmias, congestive heart failure, or mitral regurgitation;
and comorbidities such as diabetes, cerebrovascular disease,
peripheral vascular disease, chronic obstructive pulmonary
disease, and renal dysfunction. Table 1 shows a method by
which key patient variables can be used to predict an
individual patient’s operative risk of death, stroke, or
mediastinitis.
B. Morbidity Associated With Bypass Surgery
1. Neurological Events
Neurological impairment after bypass surgery may be
attributable to hypoxia, emboli, hemorrhage, and/or metabol-
ic abnormalities. Postoperative neurological deficits have
been divided into 2 types: type 1, associated with major, focal
neurological deficits, stupor, or coma; and type 2, in which
deterioration in intellectual function is evident. Adverse
cerebral outcomes are observed in '6% of patients after
bypass surgery and are equally divided between type 1 and
type 2 deficits. Predictors of cerebral complications after
bypass surgery include advanced age and a history of hyper-
tension. Particular predictors of type 1 deficits include prox-
imal aortic atherosclerosis as defined by the surgeon at
operation, history of prior neurological disease, use of the
intra-aortic balloon pump, diabetes, hypertension, unstable
angina, and increased age. Predictors of type 2 deficits
include a history of excess alcohol consumption; dysrhyth-
mias, including atrial fibrillation; hypertension; prior bypass
surgery; peripheral vascular disease; and congestive heart
failure. Estimation of a patient’s risk for postoperative stroke
can be calculated from Table 1.
2. Mediastinitis
Deep sternal wound infection occurs in 1% to 4% of patients
after bypass surgery and carries a mortality of '25%.
Predictors of this complication include obesity, reoperation,
use of both internal mammary arteries at surgery, duration
and complexity of surgery, and diabetes. An individual
patient’s risk of postoperative mediastinitis can be estimated
from Table 1.
3. Renal Dysfunction
Postoperative renal dysfunction occurs in as many as 8% of
patients. Among patients who develop postoperative renal
dysfunction (defined as a postoperative serum creatinine level
.2.0 mg/dL or an increase in baseline creatinine level of
.0.7 mg/dL), 18% require dialysis. Overall mortality among
patients who develop postoperative renal dysfunction is 19%
and approaches two thirds among patients requiring dialysis.
Predictors of renal dysfunction include advanced age, a
history of moderate or severe congestive heart failure, prior
bypass surgery, type 1 diabetes, and prior renal disease. Table
2 can be used to estimate the risk for an individual patient.
Patients with advanced preoperative renal dysfunction who
undergo CABG surgery have an extraordinarily high rate of
requiring postoperative dialysis. Among patients with a
preoperative creatinine level .2.5 mg/dL, 40% to 50%
require hemodialysis.
C. Long-Term Outcomes
Predictors of poor long-term survival after bypass surgery
include advanced age, poor LVEF, diabetes, number of
diseased vessels, and female sex. In some studies, additional
predictors include angina class, hypertension, prior MI, renal
dysfunction, and clinical congestive heart failure. Predictors
of the recurrence of angina, late MI, or any cardiac event also
include obesity and lack of use of an internal mammary
artery, as well as those factors identified above. Of these
events, the return of angina is the most common and is
primarily related to late vein-graft atherosclerosis and
occlusion.
III. Comparison of Medical Therapy Versus
Surgical Revascularization
The comparison of medical therapy with coronary surgical
revascularization is primarily based on randomized, clinical
trials and large registries. Although clinical trials have pro-
vided valuable insights, there are limitations to their interpre-
tation in the current era. Patient selection had primarily
included individuals #65 years of age, very few included
large cohorts of women, and for the most part, the studies
evaluated patients at low risk who were clinically stable. In
addition, because the studies were done in the late 1970s and
early 1980s, only 1 of the trials used arterial grafts, and even
that trial had no arterial grafts in 86% of patients. Newer
modalities of cardioprotection during cardiopulmonary by-
pass were not used, nor were minimally invasive or off-
bypass techniques. Finally, medical therapy was not opti-
mized in the trials. Lipid-lowering therapy had not yet
become standard, aspirin was not widely used, and
b-blockers were used in just half of the patients. Angioten-
sin-converting enzyme inhibitors were not being routinely
used in patients with congestive heart failure or dilated
cardiomyopathy. Accordingly, although the clinical trials
have provided important insights, their interpretation must be
viewed with caution, given the evolution in all types of
coronary therapies.
For the most part, stratification of patients in the trials was
based on the number of vessels with anatomically significant
disease, whether or not the major epicardial obstruction was
proximal, and the extent of LV dysfunction as determined by
global EF. The end point of the trials was primarily survival.
Overview: Randomized Trials
There were 3 major, randomized trials and several smaller
ones. A collaborative meta-analysis of 7 trials with a total
enrollment of 2649 patients has allowed comparison of
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outcomes at 5 and 10 years (Tables 3, 4, and 5 and the
Figure). Among all patients, the extension survival of CABG
surgical patients compared with medically treated patients
was 4.3 months at 10 years of follow-up. The benefit of
CABG compared with medical therapy in various clinical
subsets is presented below.
1. Left Main Coronary Artery Disease
The trials defined significant left main coronary artery stenosis
as a .50% reduction in lumen diameter. Median survival for
surgically treated patients was 13.3 years versus 6.6 years in
medically treated patients. Left main equivalent disease ($70%
stenosis in both the proximal left anterior descending [LAD] and
proximal left circumflex arteries) appeared to behave similarly to
true left main coronary artery disease. Median survival for
surgical patients was 13.1 years versus 6.2 years for medically
assigned patients. The benefit of surgery for left main coronary
artery disease patients continued well beyond 10 years. By 15
years, it was estimated that two thirds of patients originally
assigned to medical therapy and who survived would have had
surgery. The 15-year cumulative survival for left main coronary
artery disease patients having CABG surgery was 44% versus
31% for medical patients.
2. Three-Vessel Disease
If one defines 3-vessel disease as stenosis of 50% or more in all
3 major coronary territories, the overall extension of survival
was 7 months in CABG patients compared with medically
treated patients. Patients with class III or IV angina, those with
more proximal and severe LAD stenosis, those with worse LV
function, and/or those with more positive stress tests derived
more benefit from surgery.
3. Proximal LAD Disease
In patients with severe, proximal LAD stenosis, the relative
risk reduction due to bypass surgery compared with medical
therapy was 42% at 5 years and 22% at 10 years. This was
even more striking in patients with depressed LV function.
Extension of survival after 10 years of follow-up in various sub-
groups of patients, from a meta-analysis of 7 randomized stud-
ies. LV indicates left ventricular; VA, Veterans Administration.
TABLE 2. Risk of Postoperative Renal Dysfunction (PRD) After Coronary Artery Bypass Graft Surgery
No. of
Risk
Factors
Combinations of Preoperative Risk
Factors for PRD
Risk of PRD in Various Clinical Strata Depending on
Risk Factors and Age
CHF Reop DM Creat .1.4 ,70 y 70–79 y $80 y
0 2 2 2 2 1.9% (n5909) 7.0% (n5330) 11.8% (n568)
1 2 2 2 1 5.0% (n580) 18.4% (n576) 12.5% (n516)
2 2 1 2 5.9% (n568) 4.8% (n581) 0.0% (n51)
2 1 2 2 6.2% (n5130) 14.3% (n556) 25.0% (n54)
1 2 2 2 7.6% (n5144) 12.3% (n573) 29.4% (n517)
2 2 2 1 1 22.2% (n59) 0% (n57) 0% (n50)
2 1 2 1 20.0% (n525) 30.8% (n513) 0% (n50)
2 1 1 2 37.6% (n58) 33.3% (n53) 0% (n51)
1 2 2 1 47.4% (n519) 7.7% (n526) 44.4% (n59)
1 2 1 2 25.9% (n527) 18.2% (n511) 0% (n50)
1 1 2 2 31.6% (n519) 7.1% (n514) 100.0% (n51)
3 2 1 1 1 100% (n51) 100% (n51) 0% (n50)
1 2 1 1 8.3% (n512) 25% (n54) 0% (n51)
1 1 2 1 0.0% (n52) 33.3% (n59) 0% (n52)
1 1 1 2 33.3% (n53) 0% (n50) 0% (n50)
4 1 1 1 1 50.0% (n52) 0% (n50) 0% (n50)
CHF indicates prior congestive heart failure; Reop, redo coronary bypass operation; DM, type 1 diabetes mellitus; Creat .1.4,
preoperative serum creatinine level .1.4 mg/dL; n, observed number of patients within each clinical stratum; 2, risk factor absent;
and 1, risk factor present.
Reprinted with permission from Managano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Managano DT. Renal
dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization: the Multicenter Study
of Perioperative Ischemia Research Group. Ann Intern Med. 1998;128:194.
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4. LV Function
In patients with mildly to moderately depressed LV function,
the poorer the LV function, the greater was the potential
advantage of CABG surgery. Although the relative benefit
was similar, the absolute benefit was greater because of the
high-risk profile of these patients.
5. Symptoms and Quality of Life
Improvement in symptoms and quality of life after bypass
surgery parallels the outcome data regarding survival. Be-
yond survival, bypass surgery may be indicated to alleviate
symptoms of angina above and beyond medical therapy or to
reduce the incidence of nonfatal complications like MI,
congestive heart failure, and hospitalization. Registry studies
have shown a reduction in late MI among highest-risk
patients, such as those with 3-vessel disease, and/or those
with severe angina. In pooled analyses, a benefit on the
incidence of MI was not evident. This result likely reflected
an early increase in MI perioperatively after CABG, which
was balanced by fewer MIs over the long term among CABG
recipients. Antianginal medications were required less fre-
quently after bypass surgery. At 5 years, two thirds of bypass
patients were symptom-free compared with 38% of medically
assigned patients. By 10 years, however, these differences
were no longer significant. This result is related to the
attrition of vein grafts in the bypass group as well as
crossover of medically assigned patients to bypass surgery.
6. Loss of Benefit of Surgery
After 10 to 12 years of follow-up, there was a tendency for
the bypass surgery and medical therapy curves to converge, in
regard to both survival as well as nonfatal outcomes. This
convergence is due to a number of factors. First, the reduced
life expectancy of patients with coronary disease (regardless
of treatment) leads to a steady attrition. Second, the increased
event rate in the late follow-up period of surgically assigned
patients was likely related to the progression of native
coronary disease and graft disease over time. Finally, medi-
cally assigned patients crossed over to surgery late, thus
allowing the highest-risk medically assigned patients to gain
from the benefit of surgery later in the course of follow-up.
By 10 years, 37% to 50% of medically assigned patients had
crossed over to surgery. Tables 3, 4, and 5 and the Figure
provide estimates of long-term outcomes among patients
randomized in the trials. These tables and the Figure can be
used to estimate the general survival expectations in various
anatomic categories.
IV. Comparison of Bypass Surgery With
Percutaneous Revascularization
The results of a number of randomized, clinical trials com-
paring angioplasty and bypass surgery have been published.
The trials excluded patients in whom survival had already
been shown to be longer with bypass surgery than with
medical therapy. Also, none of the trials was sufficiently
large to detect relatively modest differences in survival
between the 2 techniques. Most of the trials did not have a
long-term follow-up, ie, 5 to 10 years, and therefore were
unable to provide clear inferences regarding long-term ben-
efit of the 2 techniques in similar populations. Also, and
perhaps most notably, only '5% of screened patients with
multivessel disease at enrolling institutions were included in
the trials. Half of the patients approached were ineligible
owing to left main coronary artery disease, insufficient
symptoms, or other reasons. Even among a large group of
patients with multivessel disease suitable for enrollment, only
half were actually randomized. It appeared that physicians
elected not to enroll many patients with 3-vessel disease in
the trials but rather refer them for bypass surgery, whereas
patients with 2-vessel disease tended to be referred for
angioplasty rather than be enrolled in the trials.
Overall, procedural complications were low for both pro-
cedures but tended to be higher with CABG surgery (Table
6). For patients randomized to angioplasty, CABG was
needed in '6% during the index hospitalization and in nearly
TABLE 3. Total Mortality at 5 and 10 Years
Trial
No. of Patients
Randomized 5-Year Mortality 10-Year Mortality
CABG
Medical
Treatment CABG
Medical
Treatment
Odds Ratio
(95% CI) CABG
Medical
Treatment
Odds Ratio
(95% CI)
VA 332 354 58 79 0.74 (0.50–1.08) 118 141 0.83 (0.61–1.14)
European 394 373 30 63 0.40 (0.26–0.64) 91 109 0.72 (0.52–0.99)
CASS 390 390 20 32 0.60 (0.34–1.08) 72 83 0.84 (0.59–1.19)
Texas 56 60 10 13 0.79 (0.31–1.97) 23 25 0.97 (0.46–2.04)
Oregon 51 49 4 8 0.44 (0.12–1.56) 14 14 0.94 (0.39–2.26)
New Zealand 51 49 5 7 0.65 (0.19–2.20) 15 16 0.94 (0.38–2.31)
New Zealand 50 50 8 8 1.00 (0.34–2.91) 17 16 1.15 (0.50–2.65)
Total 1324 1325 135 210 0.61 (0.48–0.77) 350 404 0.83 (0.70–0.98)
(10.2%) (15.8%) P,0.0001 (26.4%) (30.5%) P50.03
CABG indicates coronary artery bypass graft; CI, confidence interval; VA, Veterans Administration; and CASS, Coronary Artery
Surgery Study.
P values for heterogeneity across studies were 0.49, 0.84, and 0.95 at 5, 7, and 10 years, respectively.
Please refer to Table 7 in the full text of these guidelines (J Am Coll Cardiol. 1999;34:1275) for detailed information concerning
the trials listed here in column 1.
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20% by 1 year. The initial cost and length of stay were lower
for angioplasty than for CABG. Patients having angioplasty
returned to work sooner and were able to exercise more at 1
month. The extent of revascularization achieved by bypass
surgery was generally higher than with angioplasty. Long-
term survival was difficult to evaluate owing to the short
period of follow-up and the small sample size of the trials.
However, for the Bypass Angioplasty Revascularization In-
vestigation (BARI) trial, bypass patients had a 5-year survival
of 89.3% compared with 86.3% for angioplasty. Secondary
analysis revealed that in treated diabetic patients in the BARI
trials, CABG led to significantly superior survival compared
with percutaneous transluminal coronary angioplasty
(PTCA). However, this finding was not evident in other trials.
In long-term follow-up, the most striking difference was the
4- to 10-fold-higher likelihood of reintervention after initial
PTCA. Quality of life, physical activity, employment, and
cost were similar by 3 to 5 years after both procedures. The
BARI trial suggested higher mortality associated with PTCA
in several high-risk groups, including those with diabetes,
unstable angina, and/or non–Q wave MI, and in patients with
heart failure.
An analysis of registries generally shows data similar to those
of the trials. However, a recent analysis of '60 000 patients who
were treated in New York State in the early 1990s provides a
3-year survival analysis of patients undergoing CABG and
PTCA. After adjustment for various covariates, bypass surgery
in the New York State registry experience was associated with
longer survival in patients with severe proximal LAD stenosis
and/or 3-vessel disease. Contrariwise, patients with 1-vessel
disease not involving the proximal LAD had improved survival
with PTCA. Table 7 summarizes survival data from the New
York State registry with respect to various cohorts of patients
undergoing angioplasty or bypass surgery. These data can be
used to estimate 3-year survival expectations for patients with
various anatomic features.
V. Management Strategies
Reduction of Perioperative Mortality
and Morbidity
1. Reducing the Risk of Type 1 Brain Injury After CABG
Postoperative neurological complications represent 1 of the
most devastating consequences of CABG surgery. Type 1
TABLE 4. Subgroup Results at 5 Years
Subgroup
Overall Numbers Mortality Rates, %
Odds Ratio
(95% CI)
P for CABG Surgery vs
Medical TherapyDeaths Patients Surgical Medical
No. of diseased
vessels
1 21 271 5.4 9.9 0.54 (0.22–1.33) 0.18
2 92 859 9.7 11.7 0.84 (0.54–1.32) 0.45
3 189 1341 10.7 17.6 0.58 (0.42–0.80) ,0.001
Left main artery 39 150 15.8 36.5 0.32 (0.15–0.70) 0.004
No LAD disease
1 or 2 Vessels 50 606 8.3 8.3 1.05 (0.58–1.90) 0.88
3 Vessels 46 410 7.7 14.5 0.47 (0.25–0.89) 0.02
Left main artery 16 51 18.5 45.8 0.27 (0.08–0.90) 0.03
Overall 112 1067 8.6 12.3 0.66 (0.44–1.00) 0.05
LAD disease present
1 or 2 Vessels 63 524 9.2 14.6 0.58 (0.34–1.01) 0.05
3 Vessels 143 929 12.0 19.1 0.61 (0.42–0.88) 0.009
Left main artery 22 96 12.8 32.7 0.30 (0.11–0.84) 0.02
Overall 228 1549 11.2 18.3 0.58 (0.43–0.77) 0.001
LV function
Normal 228 2095 8.5 13.3 0.61 (0.46–0.81) ,0.001
Abnormal 115 549 16.5 25.2 0.59 (0.39–0.91) 0.02
Exercise test status
Missing 102 664 13.1 17.4 0.69 (0.45–1.07) 0.10
Normal 60 585 9.0 11.6 0.78 (0.45–1.35) 0.38
Abnormal 183 1400 9.4 16.8 0.52 (0.37–0.72) ,0.001
Severity of angina
Class I, II 178 1716 8.3 12.5 0.63 (0.46–0.87) 0.005
Class III, IV 167 924 13.8 22.4 0.57 (0.40–0.81) 0.001
CI indicates confidence interval; CABG, coronary artery bypass graft; LAD, left anterior descending coronary artery;
and LV, left ventricular.
For detailed information concerning probability value data, please see Table 8 in the full text of these guidelines
(J Am Coll Cardiol. 1999;34:1276).
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injury, in which a significant, permanent, neurological injury
is sustained, occurs in '3% of patients overall and is
responsible for a 21% mortality.
Atherosclerotic Ascending Aorta
An important predictor of this complication is the surgeon’s
identification of a severely atherosclerotic, ascending aorta
before or during the bypass operation. Perioperative athero-
embolism from aortic plaque is thought to be responsible for
approximately one third of strokes after CABG. Atheroscle-
rosis of the ascending aorta is strongly related to increased
age. Thus, stroke risk is particularly increased in patients
beyond 75 to 80 years of age. Preoperative, noninvasive
testing to identify high-risk patients has variable accuracy.
Computed tomography identifies the most severely involved
aortas but underestimates mild or moderate involvement.
Transesophageal echocardiography is useful for aortic arch
examination, but examination of the ascending aorta may be
limited by the intervening trachea. Intraoperative assessment
with epiaortic imaging is superior to both methods. Intraop-
erative palpation underestimates the high-risk aorta. The
highest-risk aortic pattern is a protruding or mobile aortic
arch plaque. An aggressive approach to the management of
patients with severely diseased ascending aortas identified by
intraoperative echocardiographic imaging reduces the risk of
postoperative stroke. For patients with aortic walls #3 mm
thick, standard treatment is used. For aortas .3 mm thick,
the cannulation, clamp, or proximal anastomotic sites may
be changed, or a no-clamp, fibrillatory arrest strategy may
be used. For high-risk patients with multiple or circumfer-
ential involvement or those with extensive middle ascend-
ing aortic involvement, replacement of the ascending aorta
under hypothermic circulatory arrest may be indicated.
Alternatively, a combined approach with off-bypass, in situ
internal mammary grafting to the LAD and percutaneous
coronary intervention to treat other vessel stenoses has
conceptual merit.
Atrial Fibrillation and Stroke
Chronic atrial fibrillation is a hazard for perioperative
stroke. Intraoperative surgical manipulation or spontane-
ous resumption of sinus rhythm during the early postop-
erative period may lead to embolism of a left atrial clot.
One approach to reduce this risk is the performance of
preoperative, transesophageal echocardiography. The ab-
sence of a left atrial clot would suggest that the operation
may proceed with acceptable risk. For elective patients, if
a left atrial clot is identified, 3 to 4 weeks of anticoagu-
lation therapy followed by restudy and then subsequent
surgery is reasonable. Few clinical trial data are available
to assist clinicians in this circumstance.
New-onset postoperative atrial fibrillation occurs in '30%
of post-CABG patients, particularly on the second and third
postoperative days, and is associated with a 2- to 3-fold
increased risk of postoperative stroke. Risk factors include
advanced age, chronic obstructive pulmonary disease, prox-
imal right coronary disease, prolonged operation, atrial ische-
mia, and withdrawal of b-blockers. The role of anticoagulants
in patients who develop post-CABG atrial fibrillation is
unclear. Aggressive anticoagulation and cardioversion may
reduce the neurological complications associated with this
arrhythmia. Early cardioversion within 24 hours of the onset
of atrial fibrillation can probably be performed safely without
anticoagulation. However, persistence of the arrhythmia be-
yond this time argues for the use of oral anticoagulants to
reduce stroke risk in patients who remain in atrial fibrillation
and/or in those for whom later cardioversion is planned.
Recent MI, LV Thrombus, and Stroke
Patients with a recent, anterior MI and residual wall-motion
abnormality are at increased risk for the development of an
LV mural thrombus and its potential for embolization. For
patients undergoing surgical revascularization after sustain-
ing an anterior MI, preoperative screening with echocardiog-
raphy may be appropriate to identify the presence of a clot.
TABLE 5. Subgroup Analysis of 5-Year Mortality by Risk Stratum
Deaths,
n
Patients,
n
Medical Treatment
Mortality Rate, %
Odds Ratio
(95% CI)
P for CABG vs
Medical Treatment
Risk strata derived by risk score*
Lowest tertile 23 406 5.5 1.18 (0.51–2.71) 0.70
Middle tertile 90 930 11.5 0.63 (0.39–1.01) 0.05
Highest tertile 153 849 23.0 0.50 (0.35–0.72) 0.001
Risk strata by stepwise risk score†
Lowest tertile 52 783 6.3 1.17 (0.66–2.07) 0.60
Middle tertile 85 784 13.9 0.55 (0.34–0.88) 0.01
Highest tertile 157 783 25.2 0.54 (0.37–0.77) 0.001
CI indicates confidence interval; CABG, coronary artery bypass graft.
Modified with permission from Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris
R, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary
Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563–570.
*Veterans Administration–type risk score5(0.703presence of class III/IV angina)1(0.373history of hypertension)1(0.833ST-
segment depression at rest)1(0.393history of myocardial infarction).
†Stepwise risk score5(0.0153age)1(0.563presence of class III/IV angina)1(0.353history of myocardial infarction)1(0.623abnormal
ejection fraction)1(0.533proximal lesion .50% in the left anterior descending coronary artery)1(0.293right coronary artery lesion
.50%)1(0.433history of diabetes)1(0.373history of hypertension).
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Detection of an acute LV mural thrombus may call for
long-term anticoagulation and reevaluation by echocardiog-
raphy to ensure resolution or organization of the thrombus
before coronary bypass surgery. Additionally, 3 to 6 months
of anticoagulation therapy is appropriate for patients with
persistent, anterior wall–motion abnormalities after coronary
bypass surgery.
Recent, Antecedent Cerebrovascular Event
A recent, preoperative cerebrovascular accident represents a
situation in which delaying surgery may reduce the periop-
erative neurological risk. In particular, evidence of a hemor-
rhagic component based on computed tomographic scan
identifies high risk for the extension of neurological damage
with cardiopulmonary bypass. It is generally believed that a
delay of 4 weeks or more after a cerebrovascular accident is
prudent, if coronary anatomy and symptoms permit, before
proceeding with CABG.
Carotid Disease and Neurological Risk Reduction
Hemodynamically significant carotid stenoses are thought to be
responsible for up to 30% of early postoperative strokes. The
trend for coronary surgery to be performed in an increasingly
elderly population and the increasing prevalence of carotid
disease in this same group of patients underscore the importance
of this issue. Perioperative stroke risk is thought to be ,2%
when carotid stenoses are ,50%, 10% when stenoses are 50%
to 80%, and 11% to 19% in patients with stenoses .80%.
Patients with untreated, bilateral, high-grade stenoses and/or
occlusions have a 20% chance of stroke. Carotid endarterectomy
for patients with high-grade stenosis is generally done preceding
or coincident with coronary bypass surgery and, with proper
teamwork in high-volume centers, is associated with a low risk
for both short- and long-term neurological sequelae. Carotid
endarterectomy performed in this fashion carries a low mortality
(3.5%) and reduces early postoperative stroke risk to ,4%, with
a concomitant 5-year freedom from stroke of 88% to 96%.
The decision about who should undergo preoperative
carotid screening is controversial. Predictors of important
carotid stenosis include advanced age, female sex, known
peripheral vascular disease, previous transient ischemic at-
tack or stroke, a history of smoking, and left main coronary
artery disease. Many centers screen all patients .65 years
TABLE 6. CABG vs PTCA: Randomized Controlled Trials
Trial*
Age, y
(% Female) CAD N
Acute Outcome, % Late Outcome, %
Primary
End Point
Primary
End
Point, %
F/U,
y
Death:
CABG
PTCA
QW-MI:
CABG
PTCA
Hosp
CABG Death
QW-
MI Angina
RR
Total/PTCA/
CABG, %
BARI 61 (26%) MV 1792 1.3 4.6 z z z 10.7 19.6 z z z 8/7/1 D 10.7 5
1.1 2.1 6.3 13.7 21.3 z z z 54/34/31 13.7
EAST 61 (26%) MV 392 1.0 10.3 z z z 6.2 19.6 12 13/13/1 D1MI1T 27.3 3
1.0 3.0† 10.1 7.1 16.6 20 54/41/22 28.8
GABI z z z (20%) MV 359 2.5 8.0 z z z 6.5 9.4 26 6/5/1 A 26 1
1.1 2.3† 8.5 2.6 4.5 29 44/27/21 29
Toulouse 67 (23%) MV 152 1.3 6.6 z z z 10.5 1.3 5.3 9/9/0 A 5.2 5
1.3 3.9 3.9 13.2 5.3 21.1† 29/15/15 21.1†
RITA 57 (19%) SV1 1011 1.2 2.4 z z z 3.6 5.2 21.5 4/3/1 D1MI 8.6 2.5§
MV‡ 0.8 3.5 4.5 3.1 6.7 31.3 31/18/19 9.8
ERACI 58 (13%) MV 127 4.6 6.2 z z z 4.7 7.8 3.2 6/3/3 D1MI1A1RR 23 1
1.5 6.3 1.5 9.5 7.8 4.8 37/14/22 53†
MASS 56 (42%) SV 142 1.4 1.4 z z z z z z z z z 2 0/0/0 D1MI1RR 3 3
(LAD) 1.4 0 11 z z z z z z 18 22/29/14 24†
Lausanne 56 (20%) SV 134 0 0 z z z 1.5 1.5 5 3/3/0 D1MI1RR 7.6 2§
(LAD) 0 0 2.9 0 2.9 6 25/12/13 36.8†
CABRI 60 (22%) MV 1054 1.3 z z z z z z 2.7 3.5 10.1 9/6/1 D 2.7 1
1.3 z z z z z z 3.9 4.9 13.9† 36/21/18 3.9
Weighted
average
60 (23%) 1.3
1.0
4.1
2.3
z z z
5.9
6.5
7.7
11.3
11.0
10.4
15.5
7.3
42.3
CABG indicates coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; CAD, coronary artery disease; QW, Q wave; MI, myocardial
infarction; Hosp CABG, required CABG after PTCA and before hospital discharge; RR, repeated revascularization; F/U, follow-up; BARI, Bypass Angioplasty
Revascularization Investigation; EAST, Emory Angioplasty Surgery Trial; GABI, German Angioplasty Bypass-surgery Investigation; RITA, Randomised Intervention
Treatment of Angina; ERACI, Estudio Randomizado Argentino de Angioplastia vs Cirugia; MASS, Medicine, Angioplasty, or Surgery Study; CABRI, Coronary Angioplasty
versus Bypass Revascularization Investigation; MV, multivessel; D, death; T, thallium defect; A, angina; SV, single vessel; and LAD, left anterior descending coronary
artery.
*References found in the complete guidelines published in J Am Coll Cardiol. 1999;34:1262–1341.
†P,0.05 comparing CABG and PTCA cohorts.
‡Included total occlusion.
§Planned 5-year follow-up (interim results).
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old. Patients with left main coronary disease are often
screened, as are those with a previous transient ischemic
attack or stroke. Preoperative central nervous system symp-
toms suggestive of vertebral basilar insufficiency should lead
to an evaluation before elective CABG.
When surgery of both carotid and coronary disease is
planned, the most common approach is to perform the
operation in a staged manner, in which the patient first has
carotid surgery followed by coronary bypass in 1 to 5 days.
Alternatively, especially if the patient has compelling cardiac
symptoms or coronary anatomy, the operations may be
performed during a single period of anesthesia, with the
carotid endarterectomy immediately preceding coronary by-
pass. Neither strategy has been established as being superior.
Stroke risk is increased if a reversed-stage procedure is used,
in which the coronary bypass operation precedes the carotid
endarterectomy by $1 day.
2. Reducing the Risk of Type 2 Brain Injury
Type 2 neurological complications are seen in '3% of
patients and are correlated with a 10% risk of postoperative
death, with 40% of patients requiring additional care in a
transitional facility after hospital discharge. Microemboliza-
tion is thought to be a major contributor to the postoperative
cerebral dysfunction after CABG. The release of microemboli
during extracorporeal circulation, involving small gaseous or
lipid emboli, may be responsible. The use of a 40-mm
arterial-line filter on the heart-lung machine circuit and
routine use of membrane oxygenators rather than bubble
oxygenators may reduce such neurological injury. Additional
maneuvers to reduce type 2 neurological injury include the
maintenance of steady, cerebral blood flow during cardiopul-
monary bypass, avoidance of cerebral hyperthermia during
and after cardiopulmonary bypass, meticulous control of
perioperative hyperglycemia, and avoidance and limitation of
postoperative cerebral edema.
3. Reducing the Risk of Perioperative
Myocardial Dysfunction
Protection in Patients With Normal LV Function
There is no universally applicable myocardial protection
technique. Among patients with preserved preoperative car-
diac function, no strong argument can currently be made for
warm versus cold and crystalloid versus blood cardioplegia.
However, certain techniques may offer a wider margin of
safety for special patient subsets.
Myocardial Protection for Acutely Depressed
Cardiac Function
Several studies have suggested that blood cardioplegia (com-
pared with crystalloid) may offer a greater margin of safety
during CABG performed on patients with acute coronary
occlusion, failed angioplasty, urgent revascularization for
unstable angina, and/or chronically impaired LV function.
Protection for Chronically Depressed LV Function
The use of a prophylactic intra-aortic balloon pump as an
adjunct to myocardial protection may reduce mortality in
patients having CABG in the setting of severe LV dysfunc-
tion (eg, LVEF ,0.25). Placement of the intra-aortic balloon
TABLE 7. Three-Year Survival by Treatment in Each Anatomic Subgroup
Coronary Anatomy Group
Patients,
n
Survival
PObserved, % Adjusted, %
1-Vessel, no LAD CABG 507 89.2 92.4 0.003
PTCA 11 233 95.4 95.3
1-Vessel, nonproximal LAD CABG 153 95.8 96.0 0.857
PTCA 4130 95.7 95.7
1-Vessel, proximal LAD CABG 1917 95.8 96.6 0.010
PTCA 5868 95.5 95.2
2-Vessel, no LAD CABG 1120 91.0 93.0 0.664
PTCA 2729 93.4 92.6
2-Vessel, nonproximal LAD CABG 850 91.3 92.3 0.438
PTCA 2300 93.3 93.1
2-Vessel, proximal LAD CABG 7242 93.5 93.8 ,0.001
PTCA 2376 92.8 91.7
3-Vessel, nonproximal LAD CABG 1984 90.1 90.3 0.002
PTCA 660 86.7 86.0
3-Vessel, proximal LAD CABG 15 873 90.1 90.3 ,0.001
PTCA 634 88.2 86.1
LAD indicates left anterior descending coronary artery; CABG, coronary artery bypass graft; and
PTCA, percutaneous transluminal coronary angioplasty. Comparative observed and adjusted 3-year
survival of patients treated with PTCA or CABG in various anatomic subgroups.
Reprinted with permission from the New York State Registry as published in Hannan EL, Racz MJ,
McCallister BD, Ryan TJ, Arani DT, Isom OW, Jones RH. A comparison of three-year survival after
coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. J Am Coll
Cardiol. 1999;33:67.
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pump immediately before operation appears to be as effective
as placement on the day preceding bypass surgery.
Adjuncts to Myocardial Protection
Although it is widely appreciated that use of the internal
mammary artery leads to improved long-term survival after
coronary bypass surgery, it has also been documented that use
of the internal mammary artery influences operative mortality
itself. Thus, internal mammary artery use should be encour-
aged in the elderly, emergent, or acutely ischemic patient and
other patient groups.
Inferior Infarct With Right Ventricular Involvement
An acutely infarcted right ventricle is at great risk for severe,
postoperative dysfunction and predisposes the patient to a
higher postoperative mortality. During operation, loss of the
pericardial constraint may lead to acute dilatation of the
dysfunctional right ventricle, which then fails to recover even
with optimal myocardial protection and revascularization.
The best defense against right ventricular dysfunction is its
recognition during preoperative evaluation. When possible,
CABG should be delayed for $4 weeks to allow the right
ventricle to recover.
4. Reducing the Systemic Consequences of
Cardiopulmonary Bypass
A variety of measures have been tried to reduce the systemic
consequences of cardiopulmonary bypass, which elicits a
diffuse inflammatory response that may cause transient or
prolonged multisystem organ dysfunction. Administration of
corticosteroids before cardiopulmonary bypass may reduce
complement activation and release of proinflammatory cyto-
kines. Proper timing and duration of corticosteroid applica-
tion are incompletely resolved. The administration of the
serine protease inhibitor aprotinin may attenuate complement
activation and cytokine release during extracorporeal circu-
lation. Unfortunately, aprotinin is relatively expensive. An-
other method to reduce the inflammatory response is periop-
erative leukocyte depletion through hematologic filtration.
5. Reducing the Risk of Perioperative Infections
Several methods exist to reduce the risk of wound infections
in patients undergoing CABG. These begin with interval
reporting to individual surgeons regarding their respective
wound infection rates and adherence to sterile operative
techniques. Additional strategies include skin preparation
with topical antiseptics, clipping rather than shaving the skin,
avoidance of hair removal, reduction of operating room
traffic, laminar-flow ventilation, shorter operation, minimiza-
tion of electrocautery, avoidance of bone wax, use of double-
glove barrier techniques for the operating room team, and
routine use of a pleural pericardial flap. Aggressive, periop-
erative glucose control in diabetics through the use of
continuous, intravenous insulin infusion reduces periopera-
tive hyperglycemia and its associated infection risk. Avoid-
ance of homologous blood transfusions after CABG may
reduce the risk of both viral and bacterial infections. This is
due to an immunosuppressive effect of transfusion. Leu-
kodepletion of transfused blood also reduces this effect. This
can be accomplished by regional blood blanks at the time of
donation or at the bedside by use of a transfusion filter.
Preoperative antibiotic administration reduces the risk of
postoperative infection 5-fold. Efficacy is dependent on
adequate drug tissue levels before microbial exposure. Ceph-
alosporins are currently the agents of choice. Table 8 identi-
fies appropriate choices, doses, and routes of therapy. A
1-day course of intravenous antimicrobials is as effective as
48 hours or more. Therapy should be administered within 30
minutes of incision and again in the operating room if the
operation exceeds 3 hours. Many centers deliver antibiotics
just before incision. One fail-safe method is to have the
anesthesiologist administer the cephalosporin after induction
but before skin incision. If deep sternal wound infection does
occur, aggressive surgical debridement and early vascularized
muscle flap coverage are the most effective methods for
treatment, along with long-term systemic antibiotics.
6. Prevention of Postoperative Dysrhythmias
Postoperative atrial fibrillation increases the length of stay,
cost, and most important, the risk of stroke. Atrial fibrillation
occurs in up to 30% of patients, usually on the second or third
postoperative day. Methods to avoid atrial fibrillation are
several. First, withdrawal of preoperative b-blockers in the
postoperative period doubles the risk of atrial fibrillation after
CABG. Thus, early reinitiation of b-blockers is critical for
avoidance of this complication. Virtually every study of
patients receiving b-blockers prophylactically has shown
benefit in lowering the frequency of atrial fibrillation. Most
have used the drug in the postoperative period, but greater
benefit may occur if b-blockade is begun before the opera-
tion. More recently, small studies of propafenone, sotalol, and
amiodarone have also shown effectiveness in reducing the
risk of postoperative atrial fibrillation. Table 9 provides a
review of pharmacological approaches in the randomized
trials. Digoxin and calcium channel blockers have no consis-
tent benefit for preventing atrial fibrillation after CABG,
although they are frequently used to control its rate after it
does occur. Currently, the routine preoperative or early
postoperative administration of b-blockers is considered stan-
dard therapy to reduce the risk of atrial fibrillation after
CABG.
7. Strategies to Reduce Perioperative Bleeding and
Transfusion Risk
Transfusion Risk
Despite the increasing safety of homologous blood transfu-
sion, concerns surrounding viral transmission during transfu-
sion remain. Currently, the risks are likely very low and have
been estimated to be 1/493 000 for human immunodeficiency
virus, 1/641 000 for human T-cell lymphotrophic virus,
1/103 000 for hepatitis C virus, and 1/63 000 for hepatitis B
virus.
Perioperative Bleeding
Risk factors for blood transfusion after CABG include ad-
vanced age, low preoperative red blood cell volume, preop-
erative aspirin therapy, urgent operation, duration of cardio-
pulmonary bypass, recent thrombolytic therapy, reoperation,
and differences in heparin management. Institutional proto-
cols that establish minimum thresholds for transfusion lead to
a reduced number of units transfused and the percentage of
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patients requiring blood. Additional strategies can reduce the
transfusion requirement after CABG. For stable patients,
aspirin and other antiplatelet drugs may be discontinued 7
days before elective CABG. Aprotinin, a serum protease
inhibitor with antifibrinolytic activity, also decreases postop-
erative blood loss and transfusion requirements in high-risk
patients. Although there has been some concern that aprotinin
may reduce early graft patency, recent studies have failed to
document this effect. Routine use of aprotinin is limited by its
high cost. Multidisciplinary approaches to conserve blood in
single institutions appear to be effective.
For patients without exclusions, such as low hemoglobin
values, heart failure, unstable angina, left main coronary
artery disease, or advanced anginal symptoms, self-donation
of 1 to 3 units of red blood cells over 30 days before operation
reduces the need for homologous transfusion during or after
operation. Donation immediately before cardiopulmonary
bypass yields a higher platelet and hemoglobin count com-
pared with simple hemodilution without pre–cardiopulmo-
nary bypass blood harvesting.
8. Antiplatelet Therapy for Saphenous Vein Graft Patency
Aspirin significantly reduces vein graft closure during the
first postoperative year. The aspirin should be started within
24 hours after surgery because its benefit on saphenous vein
graft patency is lost when begun later. Dosing regimens from
as little as 100 mg/d to as much as 325 mg TID appear to be
efficacious. Ticlopidine offers no advantage over aspirin but
is an alternative in truly aspirin-allergic patients. Life-
threatening neutropenia is a rare but recognized side effect.
Clopidogrel offers the potential for fewer side effects com-
pared with ticlopidine as an alternative in aspirin-allergic
patients. Its incidence of severe leukopenia is rare.
9. Pharmacological Management of Hyperlipidemia
Aggressive treatment of hypercholesterolemia reduces pro-
gression of atherosclerotic vein graft disease in patients after
bypass surgery. Statin therapy has been shown to reduce
saphenous vein graft disease progression over the ensuing
years after bypass. Patients with unknown low-density li-
poprotein (LDL) cholesterol levels after bypass should have
cholesterol levels determined and treated pharmacologically
if the LDL exceeds 100 mg/dL. Patients with treated LDL
cholesterol should have their low-fat diet and cholesterol-
lowering medications continued after bypass surgery to re-
duce subsequent graft attrition. Data regarding the benefit of
cholesterol lowering after bypass surgery are most supported
by studies that have used HMG CoA (3-hydroxy-3-
methylglutaryl coenzyme A) reductase inhibitors, particularly
targeting LDL levels to ,100 mg/dL.
TABLE 8. Prophylactic Antimicrobials for Coronary Artery Bypass Graft Surgery
Cephalosporins
Equivalent Efficacy
IV Dosing Regimens
Dose and Interval Cost per Dose Comments
Cefuroxime 1.5 g preoperatively
1.5 g after CPB
1.5 g Q12348
$6.33/1.5 g First-line agents; low
toxicity; pharmacokinetics
vary; shorter prophylaxis
duration ,24 h may be
equally efficacious for
cefuroxime
Cefamandole, cefazolin 1 g preoperatively $6.27/g
1 g at sternotomy $0.90/g
1 g after CPB
1 g Q6348 (Initial dose to be given
30–60 minutes before skin incision)
Vancomycin 1 g Q12/h/until lines/tubes out
At least 2 doses
$5.77/g Reserved for
penicillin-allergic; justified
(During 30–60-minute infusion timed to
end before skin incision)
in periods of
methicillin-resistant
Staphylococcus species
outbreaks;
vancomycin-resistant
Enterococcus problem is on
horizon; more likely to
require vasopressor agent
perioperatively
CPB indicates cardiopulmonary bypass.
Data taken from (1) Townsend TR, Reitz BA, Bilker WB, Bartlett JG. Clinical trial of cefamandole, cefazolin, and cefuroxime for
antibiotic prophylaxis in cardiac operations. J Thorac Cardiovasc Surg. 1993;106:664–670. (2) Antimicrobial prophylaxis in surgery.
Med Lett Drugs Ther. 1997;39:97–101. (3) Vuorisalo S, Pokela R, Syrjala H. Comparison of vancomycin and cefuroxime for infection
prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol. 1998;19:234–239. (4) Romanelli VA, Howie MB,
Myerowitz PD, Zvara DA, Rezaei A, Jackman DL, Sinclair DS, McSweeny TD. Intraoperative and postoperative effects of vancomycin
administration in cardiac surgery patients: a prospective, double-blind, randomized trial. Crit Care Med. 1993;21:1124–1131.
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10. Hormonal Manipulation
While observational studies have suggested that hormone replace-
ment therapy in postmenopausal women leads to a reduction in
all-cause mortality, a recent, randomized trial for secondary coro-
nary prevention failed to show a beneficial effect on the overall rate
of coronary events. Thus, hormone replacement therapy should be
considered in postmenopausal women after bypass when, in the
physician’s judgment, the potential coronary benefit is not offset by
an increased risk of uterine or breast cancer.
11. Smoking Cessation
Smoking cessation is the single, most important risk-
modification goal after CABG in patients who smoke.
Smoking cessation leads to less recurrent angina, improved
physical function, fewer admissions, maintenance of em-
ployment, and improved survival. Treatment individual-
ized to the patient is crucial. Depression may be an
important complicating factor and should be approached
with behavioral and drug therapy. Nicotine replacement
with a transdermal patch, nasal spray, gum, or inhaler is
beneficial. A sustained-release form of bupropion, an
antidepressant similar to selective serotonin reuptake in-
hibitors, reduces the nicotine craving and anxiety of
smokers who quit. All smokers should receive educational
counseling and be offered smoking cessation therapy after
CABG (Table 10).
TABLE 9. Pharmacological Strategies for Prevention of Atrial Fibrillation (AF) After Coronary Artery Bypass Graft Surgery
Treatment Timing Dose/Route AF Incidence, % Comments
Frontline strategies
Resumption of patient’s preoperative
b-blocker
Postoperative resumption Same as preoperative b-Blocker stopped; 38.1%
Continued P50.02 17.1%
Resumption of b-blocker
reduced AF by 45%
b-Blocker stopped; 28%
Continued P50.01 6%
Nearly 5-fold decrease
in incidence; if no longer
needed after
revascularization, may
taper as outpatient
b-Blockers (propranolol
prototypical)
Postoperative initiation
(1067 h postoperatively)
5 mg orally 4 times per
day
Control 23%
Propranolol 9.8%
P50.02
Reduced AF by 43%;
inexpensive, low dose
Almost all b-blockers evaluated Postoperatively Varies Significantly reduced vs
placebo
Odds ratio 0.17;
confidence interval
0.03–0.98 in favor of
b-blocker over controls
in meta-analysis
Atenolol Preoperatively (begun 72 h
before operation)
50 mg Orally twice a day Control 37%
Atenolol 3%
P50.001
Excellent option if
preoperative phase
practical
Sotalol Preoperatively through
postoperatively
160 mg AM of operation,
then 160 mg BID PO
Control 29%
Sotalol 10%
Class III properties;
sotalol not tolerated in
10% of patients
Magnesium sulfate Postoperatively Continuous IV infusion for
a total of 178 mEq over
first 4 postoperative days
Control 28%
Mg supplement 14%
P50.02
Goal is normal serum
magnesium:
$1 mmol/L, ,2 mEq/L,
which is usually low
after cardiopulmonary
bypass
Alternative/niche strategies
Amiodarone Preoperatively through
postoperatively
600 mg Orally daily for 7
days preoperatively; then
200 mg PO daily
postoperatively; stop at
discharge; total54.8 g
Control 53%
Amiodarone 25%
P50.003
Mixed group of coronary
and valve patients,
explaining very high AF
incidence
Amiodarone Postoperatively 300 mg Intravenous
bolus; then 1.2 g over
24 h for 2 days; then
900 mg every 24 h for 2
days, for a total of 4.5 g
Control 21%
Amiodarone 5%
P50.05
Coronary bypass patients
only in this study
Propafenone Postoperatively 300 mg Orally twice a
day for 7 days
Propafenone 12%
Atenolol 11%
P5NS
Propafenone offers a
less negative inotropic
option for poor left
ventricular function
population
For details about the trials from which these data were derived, please refer to Table 13 of the full text of these guidelines (J Am Coll Cardiol. 1999;34:1294).
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12. Cardiac Rehabilitation
Cardiac rehabilitation, including early ambulation during
hospitalization, outpatient prescriptive exercise, family edu-
cation, and dietary and sexual counseling, has been shown to
improve outcomes after CABG. The benefits include better
physical mobility and perceived health. A higher proportion
of rehabilitated patients are working at 3 years after CABG.
The benefits of rehabilitation extend to the elderly and to
women. Cardiac rehabilitation reinforces pharmacological
therapy and smoking cessation and should be offered to all
eligible patients after CABG.
13. Emotional Dysfunction and
Psychosocial Considerations
Lack of social participation and low religious strength are
independent predictors of death in elderly patients undergo-
ing CABG. Although controversial, the high prevalence of
depression after bypass surgery may reflect a high prevalence
preoperatively. Cardiac rehabilitation has a highly beneficial
effect in patients who are moderately or severely depressed.
Evaluation of social supports and attempts to identify and
treat underlying depression should be part of routine post-
CABG care.
14. Rapid Sustained Recovery After Operation
Rapid recovery and early discharge are standard goals after
CABG. The shortest in-hospital postoperative stays are
followed by the fewest rehospitalizations. Important com-
ponents of “fast-track” care are careful patient selection,
patient and family education, early extubation, prophylac-
tic antiarrhythmic therapy, dietary considerations, early
ambulation, early outpatient telephone follow-up, and
careful coordination with other physicians and healthcare
providers.
15. Communication Between Caregivers
Maintenance of appropriate and timely communication be-
tween treating physicians regarding care of the patient is
crucial. When possible, the primary care physician should
follow up the patient during the perioperative course. The
referral physician needs to provide clear, written reports of
the findings and recommendations to the primary care phy-
sician, including discharge medications and dosages along
with long-term goals.
VI. Impact of Evolving Technology
A. Less-Invasive Coronary Bypass Surgery
Technical modifications of CABG have been developed to
decrease the morbidity of the operation, either by using
limited incision or by eliminating cardiopulmonary bypass.
Currently, “less-invasive” CABG surgery can be divided into
3 categories: (1) off-bypass CABG performed through a
median sternotomy with a smaller skin incision, (2) mini-
mally invasive direct CABG (MID-CAB) performed through
a left anterior thoracotomy without cardiopulmonary bypass,
and (3) port-access CABG with femoral-to-femoral cardio-
pulmonary bypass and cardioplegic arrest with limited
incision.
TABLE 10. Proven Management Strategies to Reduce Perioperative and Late Morbidity and Mortality
Timing
Class
Indication Intervention Comments
Preoperative
Carotid screening I Carotid duplex ultrasound in
defined population
Carotid endarterectomy if stenosis
$80%
Perioperative
Antimicrobials I Prophylactic antimicrobials Table 8
Antifibrinolytics IIa Aprotinin in selected groups Significant reduction in blood
transfusion requirement
Antiarrhythmics I b-Blockers to prevent
postoperative atrial
fibrillation
Propafenone or amiodarone are
alternatives if contraindication to
b-blocker (Table 9)
Anti-inflammatory drugs IIa Minimize diffuse
inflammatory response to
cardiopulmonary bypass
Postoperative
Antiplatelet agents I Aspirin to prevent early
vein-graft attrition
Ticlopidine or clopidogrel are
alternatives if contraindications to
aspirin
Lipid-lowering therapy I Cholesterol-lowering agent
plus low-fat diet if low-
density lipoprotein
cholesterol .100 mg/dL
3-Hydroxy-3-methyglutaryl/coenzyme
A reductase inhibitors preferred if
elevated low-density lipoprotein is
major aberration
Smoking cessation I Smoking cessation
education, and offer
counseling and
pharmacotherapies
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Off-bypass coronary surgery is performed on a beating
heart after reduction of cardiac motion with a variety of
pharmacological and mechanical devices. These include
slowing the heart with b-blockers and calcium channel
blockers and use of a mechanical stabilizing device to isolate
and stabilize the target vessel. Retraction techniques may
elevate the heart to allow access to vessels on the lateral and
inferior surfaces of the heart. Because this technique gener-
ally uses a median sternotomy, its primary benefit is the
avoidance of cardiopulmonary bypass, not a less extensive
incision.
MID-CAB refers to bypass surgery without median ster-
notomy and without the use of cardiopulmonary bypass.
Generally, this is performed with a small left anterior thora-
cotomy, exposing the heart through the fourth intercostal
interspace with access to the LAD and diagonal branches and
occasionally, the anterior marginal vessels. The right coro-
nary artery can be approached by using a right anterior
thoracotomy. MID-CAB procedures are generally performed
on only 1 or 2 coronary targets. Observational studies have
suggested that MID-CAB is associated with a reduced aver-
age length of stay and an earlier return to work. Although
initial reports of 2-year actuarial and event-free survival are
encouraging, the data must be viewed with caution. Because
the number of anastomoses performed on a beating heart is
usually 1 or occasionally 2, the potential long-term effects of
incomplete revascularization are unknown.
The closed-chest, port-access, video-assisted CABG oper-
ation uses cardiopulmonary bypass and cardioplegia of a
globally arrested heart. Vascular access for cardiopulmonary
bypass is achieved via the femoral artery and vein. A
triple-lumen catheter with an inflatable balloon at its distal
end is used to achieve endovascular aortic occlusion, cardio-
plegia delivery, and LV decompression. With cardiopulmo-
nary bypass and cardioplegic arrest, CABG can be performed
with video assistance on a still and decompressed heart
through several small ports. In comparison with the MID-
CAB, port access allows access to different areas of the heart,
thus facilitating more complete revascularization, and the
motionless heart may allow a more accurate anastomosis.
Compared with conventional CABG, median sternotomy is
avoided. However, potential morbidity of the port-access
operation includes multiple wounds at port sites, the limited
thoracotomy, and the groin dissection for femoral-femoral
bypass. Vigorous scrutiny of the long-term benefits versus
risks of port access is required.
B. Arterial and Alternate Conduits
Another area of evolving technology is the use of arterial and
alternate conduits. The 5-year patency of coronary artery–
vein bypass grafts is 74%, and at 10 years, just 41%.
Contrariwise, patency rates of the internal mammary artery
implanted into the LAD are as high as 83% at 10 years. As a
consequence of improved patency, patients receiving an LAD
graft with an internal mammary artery have improved sur-
vival compared with patients receiving only vein grafts.
Currently, routine use of the left internal mammary artery for
LAD grafting with supplemental saphenous vein grafts to
other coronary lesions is generally accepted as a standard
grafting method. The use of bilateral internal mammary
arteries appears to be safe and efficacious. However, there is
a higher rate of deep sternal wound infection when both
internal mammary arteries are used. This is particularly true
for patients with obesity and diabetes and perhaps for those
requiring prolonged ventilatory support. The benefits of
bilateral internal mammary artery use include lower rates of
recurrent angina, MI, and need for reoperation and a trend for
better survival. Recently, the radial artery has been used more
frequently as a conduit for coronary bypass surgery. Five-
year patency appears to be in the range of 85% (compared
with nearly 90% for the internal mammary graft). In patients
for whom mammary artery, radial artery, and standard vein
conduits are unavailable, the in situ right gastroepiploic
artery, the inferior epigastric free artery graft, and either
lesser saphenous or upper-extremity vein conduits have been
used. Long-term patency of these alternative grafts has not
been extensively studied.
C. Percutaneous Technology
Technological improvements in percutaneous coronary an-
gioplasty have included the introduction of new devices and
improved medical therapy of patients in whom angioplasty is
performed. The most notable improvement has been the
introduction of intracoronary stents that have reduced late
restenosis and the frequency with which emergency bypass
surgery is required after PTCA. Intracoronary stents have
been used to treat saphenous vein graft stenosis in patients
with previous CABG. However, stented patients still have an
'25% combined rate of death, MI, need for repeat CABG, or
re-revascularization of the target vessel. For some patients,
hybrid procedures may be the best choice, such as the
combined use of CABG surgery and coronary angioplasty.
Such an approach is relevant to the patient whose ascending
aorta is involved with severe atherosclerosis, for which the
implantation of free vein grafts or arterial grafts leads to risk
for atheroembolism. In such a patient, the use of in situ
internal mammary artery grafting without cardiopulmonary
bypass combined with additional coronary angioplasty in
other diseased vessels represents a strategy to provide com-
plete revascularization without the concomitant risks of
cardiopulmonary bypass and/or manipulation of the ascend-
ing aorta.
D. Transmyocardial Revascularization
A fourth area that is rapidly evolving is transmyocardial
revascularization. The use of transmyocardial laser revascu-
larization has generally been performed surgically for pa-
tients with severe angina refractory to medical therapy and
who are not suitable candidates for standard surgical revas-
cularization, PTCA, or heart transplant. While several studies
have suggested improvement in angina severity with
transmyocardial laser revascularization, the mechanism by
which angina improves and the overall benefit on long-term
angina and/or survival await further clarification.
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VII. Special Patient Subsets
A. Elderly Patients
Elderly patients being considered for CABG have a higher
average risk for mortality and morbidity in a direct relation to
age, LV function, extent of coronary disease, and comorbid
conditions and whether the procedure is urgent, emergent, or
a reoperation. Nonetheless, functional recovery and sustained
improvement in the quality of life can be achieved in the
majority of such patients. The patient and physician together
must explore the potential benefits of improved quality of life
with the attendant risks of surgery versus alternative therapies
that take into account baseline functional capacities and
patient preferences. Age alone should not be a contraindica-
tion to CABG if it is thought that long-term benefits outweigh
the procedural risk.
B. Women
A number of earlier reports had suggested that female sex was an
independent risk factor for mortality and morbidity after CABG.
More recent studies have suggested that women on average have
a disadvantageous, preoperative clinical profile that accounts for
much of this perceived difference. Thus, the issue is not
necessarily sex itself but the comorbid conditions that are
particularly associated with the later age at which women
present for coronary surgery. Thus, CABG should not be
delayed in or denied to women who have appropriate
indications.
C. Diabetic Patients
Coronary heart disease is the leading cause of death among adult
diabetics and accounts for 3 times as many deaths among
diabetics as among nondiabetics. While CABG carries an
increased morbidity and mortality in diabetics, data suggest that
in appropriate candidates, the absolute risk reduction provided
by successful revascularization remains high. The BARI trial
suggested that diabetics with multivessel coronary disease de-
rived advantage from bypass surgery compared with angio-
plasty. Several of the other randomized trials, albeit with smaller
numbers of patients, failed to show this trend. Diabetics who are
candidates for renal transplantation have a particularly high
incidence of coronary artery disease, even in the absence of
symptoms or signs. In appropriate candidates, CABG appears to
offer morbidity and mortality benefit in such patients.
D. Patients With Chronic Obstructive
Pulmonary Disease
Because CABG is associated with variable degrees of post-
operative respiratory insufficiency, it is important to identify
patients at particular risk for pulmonary complications. The
intent is to treat reversible problems that may contribute to
respiratory insufficiency in high-risk patients, with the hope
of avoiding prolonged periods of mechanical ventilation after
CABG. High-risk patients often benefit from preoperative
antibiotics, bronchodilator therapy, a period of cessation from
smoking, perioperative incentive spirometry, deep-breathing
exercises, and chest physiotherapy. If pulmonary venous
congestion or pleural effusions are identified, diuresis often
improves lung performance.
Although preoperative spirometry directed to identifying
patients with a low (eg, ,1 L) 1-second forced expiratory
volume has been used by some to qualify or disqualify
candidates for CABG, clinical evaluation of lung function is
likely as important if not more so. Patients with advanced
chronic obstructive pulmonary disease are at particular risk
for postoperative arrhythmias that may be fatal. While mod-
erate to severe degrees of obstructive pulmonary disease
represent a significant risk factor for early mortality and
morbidity after CABG, it is also true that with careful
preoperative assessment and treatment of the underlying
pulmonary abnormality, many such patients are successfully
carried through the operative procedure.
E. Patients With End-Stage Renal Disease
Coronary artery disease is the most important cause of
mortality in patients with end-stage renal disease. Many of
such patients have diabetes and other coronary risk factors,
including hypertension, myocardial dysfunction, abnormal
lipids, anemia, and increased plasma homocysteine levels.
Although patients on chronic dialysis are at higher risk when
undergoing coronary angioplasty or bypass, they are at even
higher risk with conservative medical management. Thus, in
patients with modest reductions in LV function, significant
left main or 3-vessel disease, and/or unstable angina, coro-
nary revascularization can lead to relief of coronary symp-
toms, improvement in overall functional status, and improved
long-term survival in this select high-risk patient population.
F. Reoperative Patients
Operative survival and long-term benefit of reoperative CABG
are distinctly inferior to first-time operations. Patients undergo-
ing repeated CABG have higher rates of postoperative bleeding,
perioperative MI, and neurological and pulmonary complica-
tions. Nevertheless, reasonable 5- and 10-year survival rates
after reoperation for coronary disease can be achieved, and the
operation is appropriate if the severity of symptoms and antici-
pated benefit justify the immediate risk. Data suggest that the
need for reoperation is less common in patients undergoing
internal mammary artery grafting to the LAD. More recently,
short-term follow-up studies suggest that patients undergoing
multiple arterial grafts have even lower rates of reoperation.
These early results are consistent with the known superior graft
patency of arterial conduits compared with vein grafts.
G. Concomitant Peripheral Vascular Disease
The presence of clinical and subclinical peripheral vascular
disease is a strong predictor of increased hospital and long-term
mortality rates in patients undergoing CABG. However, the
absolute benefit offered by coronary revascularization is ele-
vated in patients with peripheral vascular disease, particularly
those with 3-vessel coronary disease, more advanced angina,
and/or a depressed LVEF. Excess perioperative mortality in such
patients is related to an increased incidence of heart failure and
dysrhythmias rather than peripheral arterial complications.
H. Poor LV Function
Patients with severe LV dysfunction have increased periopera-
tive and long-term mortality compared with patients with normal
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LV function. However, studies suggest that the beneficial effects
of myocardial revascularization in patients with ischemic heart
disease and severe LV dysfunction are sizeable when compared
with medically treated patients of similar status in terms of
symptom relief, exercise tolerance, and survival.
I. CABG in Acute Coronary Syndromes
Coronary bypass surgery offers a survival advantage com-
pared with medical therapy in patients with unstable angina
and LV dysfunction, particularly in the presence of 3-vessel
disease. However, the risk of bypass surgery in patients with
unstable or postinfarction angina or early after non–Q wave
infarction and during acute MI is increased severalfold
compared with patients with stable angina. Although this risk
is not necessarily higher than that with medical therapy, it has
led to the argument to consider angioplasty or to delay CABG
in such patients if medical stabilization can be easily
accomplished.
VIII. Institutional and Operator Competence
Studies suggest that mortality after CABG is higher when
carried out in institutions that annually perform fewer than a
minimum number of cases. Similar conclusions have been
drawn regarding individual surgeons’ volumes. This obser-
vation strengthens the argument for careful outcome tracking
and supports the monitoring of institutions or individuals who
annually perform ,100 cases. It is also true that there is a
wide variation in risk-adjusted mortality rates in low-volume
situations. Thus, some institutions and practitioners maintain
excellent outcomes despite relatively low volumes.
Outcome reporting in the form of risk-adjusted mortality
rates after bypass has been effective in reducing mortality
rates nationwide. Public release of hospital and physician-
specific mortality rates has not been shown to drive this
improvement and has failed to effectively guide consumers or
alter physician referral patterns.
IX. Cost-Effectiveness of Bypass Surgery
A variety of studies of CABG have found the technique to be
cost-effective in patients for whom survival and/or symptom-
atic benefit is demonstrable. Within these subsets, the cost-
effectiveness of CABG compares favorably with that of other
accepted medical therapies.
When compared with PTCA, the initial hospital cost of
CABG is significantly higher. However, by 5 years, the
cumulative cost of PTCA compared with initial surgical
therapy is within 5% of CABG, or a difference of ,$3000.
Observational studies showing a poorer survival effect of
PTCA in patients with more advanced disease suggest that
there may be a significant cost gradient for PTCA as the
extent of disease increases, which is not apparent for coronary
bypass surgery.
X. Indications
A. Indications for CABG in Asymptomatic or
Mild Angina
Class I
1. Significant left main coronary artery stenosis.
2. Left main equivalent: significant (>70%) stenosis of
proximal LAD and proximal left circumflex artery.
3. Three-vessel disease. (Survival benefit is greater in
patients with abnormal LV function; eg, with an EF
<0.50.)
Class IIa
1. Proximal LAD stenosis with 1- or 2-vessel disease.*
Class IIb
1. One- or 2-vessel disease not involving the proximal
LAD.†
Class III
See text.
B. Indications for CABG in Stable Angina
Class I
1. Significant left main coronary artery stenosis.
2. Left main equivalent: significant (>70%) stenosis of
proximal LAD and proximal left circumflex artery.
3. Three-vessel disease. (Survival benefit is greater
when LVEF is <0.50.)
4. Two-vessel disease with significant proximal LAD
stenosis and either EF <0.50 or demonstrable ische-
mia on noninvasive testing.
5. One- or 2-vessel coronary artery disease without
significant proximal LAD stenosis, but with a large
area of viable myocardium and high-risk criteria on
noninvasive testing.
6. Disabling angina despite maximal medical therapy,
when surgery can be performed with acceptable
risk. If angina is not typical, objective evidence of
ischemia should be obtained.
Class IIa
1. Proximal LAD stenosis with 1-vessel disease.*
2. One- or 2-vessel coronary artery disease without
significant proximal LAD stenosis, but with a mod-
erate area of viable myocardium and demonstrable
ischemia on noninvasive testing.
Class III
1. One- or 2-vessel disease not involving significant
proximal LAD stenosis, in patients (1) who have
mild symptoms that are unlikely due to myocardial
ischemia or have not received an adequate trial of
medical therapy and (A) have only a small area of
viable myocardium or (B) have no demonstrable
ischemia on noninvasive testing.
2. Borderline coronary stenoses (50% to 60% diameter
in locations other than the left main coronary artery)
*Becomes Class I if extensive ischemia documented by noninvasive study and/or an LVEF ,0.50%.
†If a large area of viable myocardium and high-risk criteria on noninvasive testing, becomes Class I.
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and no demonstrable ischemia on noninvasive
testing.
3. Insignificant (<50% diameter) coronary stenosis.
C. Indications for CABG in Unstable
Angina/Non–Q Wave MI
Class I
1. Significant left main coronary artery stenosis.
2. Left main equivalent: significant (>70%) stenosis of
proximal LAD and proximal left circumflex artery.
3. Ongoing ischemia not responsive to maximal non-
surgical therapy.
Class IIa
1. Proximal LAD stenosis with 1- or 2-vessel disease.*
Class IIb
2. One- or 2-vessel disease not involving the proximal
LAD.†
Class III
See text.
D. Indications for CABG in ST-Segment Elevation
(Q-Wave) MI
Class I
None.
Class IIa
1. Ongoing ischemia/infarction not responsive to max-
imal nonsurgical therapy.
Class IIb
1. Progressive LV pump failure with coronary stenosis
compromising viable myocardium outside the initial
infarct area.
2. Primary reperfusion in the early hours (<6 to 12
hours) of an evolving ST-segment elevation MI.
Class III
1. Primary reperfusion late (>12 hours) in evolving
ST-segment elevation MI without ongoing ischemia.
E. Indications for CABG in Poor LV Function
Class I
1. Significant left main coronary artery stenosis.
2. Left main equivalent: significant (>70%) stenosis of
proximal LAD and proximal left circumflex artery.
3. Proximal LAD stenosis with 2- or 3-vessel disease.
Class IIa
1. Poor LV function with significant viable, noncon-
tracting, revascularizable myocardium without any
of the aforementioned anatomic patterns.
Class III
1. Poor LV function without evidence of intermittent
ischemia and without evidence of significant revas-
cularizable, viable myocardium.
F. Indications for CABG in Life-Threatening
Ventricular Arrhythmias
Class I
1. Left main coronary artery stenosis.
2. Three-vessel coronary disease.
Class IIa
1. Bypassable 1- or 2-vessel disease causing life-
threatening ventricular arrhythmias.‡
2. Proximal LAD disease with 1- or 2-vessel disease.‡
Class III
1. Ventricular tachycardia with scar and no evidence of
ischemia.
G. Indications for CABG After Failed PTCA
Class I
1. Ongoing ischemia or threatened occlusion with sig-
nificant myocardium at risk.
2. Hemodynamic compromise.
Class IIa
1. Foreign body in crucial anatomic position.
2. Hemodynamic compromise in patients with impair-
ment of coagulation system and without previous
sternotomy.
Class IIb
1. Hemodynamic compromise in patients with impair-
ment of coagulation system and with previous
sternotomy.
Class III
1. Absence of ischemia.
2. Inability to revascularize owing to target anatomy or
no-reflow state.
H. Indications for CABG in Patients With
Previous CABG
Class I
1. Disabling angina despite maximal noninvasive ther-
apy. (If angina is not typical, then objective evidence
of ischemia should be obtained.)
Class IIa
1. Bypassable distal vessel(s) with a large area of
threatened myocardium on noninvasive studies.
Class IIb
1. Ischemia in the non-LAD distribution with a patent
internal mammary graft to the LAD supplying func-
tioning myocardium and without an aggressive at-
tempt at medical management and/or percutaneous
revascularization.
Class III
See text.
KEY WORDS: ACC/AHA Practice Guidelines n bypass n angioplasty
n morbidity n mortality n revascularization n risk factors
*Becomes Class I if extensive ischemia documented by noninvasive study and/or an LVEF ,0.50.
†If a large area of viable myocardium and high-risk criteria on noninvasive testing, becomes Class I.
‡Becomes Class I if arrhythmia is resuscitated sudden cardiac death or sustained ventricular tachycardia.
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